The DOJ just moved certain marijuana products from Schedule I to Schedule III, officially recognizing medical use and triggering a major tax shift that benefits large cannabis companies. The change leaves federal criminal penalties and state laws largely intact while setting up a fast-tracked DEA review for broader rescheduling. Big operators stand to gain the most as key tax burdens disappear, even as the broader legal landscape for users and small businesses barely changes. Ring of Fire’s Josh G. discusses.
